Company intelligence / Profile preview

SPIMACO

Riyadh, Riyadh, Saudi Arabia

Ownership: Private
Employees: ~1182
Development stage: Other

Overview

SPIMACO is one of the largest pharmaceutical companies in the Middle East and North Africa, producing over 2 billion units yearly across 16 countries. It has leading sales in Saudi Arabia's private sector, active research collaborations (including with WHO), major manufacturing agreements, and ongoing expansion into cancer drugs and biopharmaceuticals. Clinical result summaries for pipeline programs are not publicly available.

Therapeutic areas: OncologyInfectious DiseasesOther
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

AstraZeneca (manufacturing agreement)World Health Organisation (research collaboration)Leading drug manufacturers (undisclosed details)

Beyond the preview

Go deeper on SPIMACO.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SPIMACO.

Explore the full profile